Inferra AI / Company / HROW

Harrow, Inc.

HROW · Health Care

Last earnings Aug 10, 2026

Key results

Revenuequarter

$100 million

revenue of over $100 million

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Quarterly revenuequarter

$44.2 million

Quarterly revenue of $44.2 million, including a non-recurring gross-to-net revenue adjustment connected to new VEVYE commercial coverage, which lowered Q1 revenue by approximately $8 million IHEEZO &reg

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

“Although our first-quarter reported revenue reflects an estimated $8 million gross-to-net reduction associated with our new commercial coverage for VEVYE, this adjustment does not reflect the profitable, recurring , and significant patient base established during the quarter.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Total revenuequarter

$ 44,203,000

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, 2026 2025 Total revenues $ 44,203,000 $ 47,831,000 Cost of sales (17,158,000 ) (15,524,000 ) Gross profit 27,045,000 32,307,000 Selling, general and administrative 43,230,000 40,513,000 Research and development 5,895,000 3,026,000 Total operating expenses 49,125,000 43,539,000 Loss from operations (22,080,000 ) (11,232,000 ) Interest expense, net (5,497,000 ) (6,548,000 ) Income tax expense (25,000 ) - Net loss $ (27,602,000 ) $ (17,780,000 ) Net loss per share: Basic and diluted $ (0.74 ) $ (0.50 ) -END- Harrow Announces First Quarter 2026 Financial Results Page 5 May 11, 2026 HARROW, INC.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

VEVYE revenuequarter

$20.9 million

Consequently, our reported VEVYE revenue of $20.9 million for the quarter was approximately $8 million below what we believe it would have been had we made these operational adjustments at the beginning of the year.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

This commercial engine, combined with cash from our creativity in unlocking value from underappreciated assets across our portfolio, underpins our unified corporate initiative to achieve $250 million in quarterly revenue by the end of 2027.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Financials revenuequarter

$44.2 million

Financials Revenues of $44.2 million for the first quarter of 2026 represent an 8% decrease over the prior-year first quarter

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

revenues of $47.8 million.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

AI analysis

Q1 2026 · reported May 11, 2026

Based on: Earnings release + Q1 2026 deck + parent 8-K + 10-K — transcript not held

Revenue · Q1 2026

$100M

EX-99 · May 11, 2026

Quarterly revenue · Q1 2026

$44.2M

EX-99 · May 11, 2026

Total revenue · Q1 2026

$ 44,203,000

EX-99 · May 11, 2026

VEVYE revenue · Q1 2026

$20.9M

EX-99 · May 11, 2026

The quarter in charts

Segment mix

Business-unit revenue, as stated

Segment revenue figures as stated in the event record.

Headline figures

Metric	Q1 2026	Prior qtr	Year ago
Revenue	$100 million	—	—
Quarterly revenue	$44.2 million	—	—
Total revenue	$ 44,203,000	—	—
VEVYE revenue	$20.9 million	—	—
Financials revenue	$44.2 million	—	—

EX-99 · May 11, 2026

Guidance · company-stated

Direction: raised

No guidance located in the held release

Stated figure60%

“7 million, an increase of 60% sequentially, and 11% year over year Reiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure) VEVYE ® delivered quarterly revenue of $29.”

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2026 December 31, 2025 ASSETS Cash and cash equivalents $ 94,644,000 $ 72,927,000 All other current assets 131,740,000 138,823,000 Total current assets 226,384,000 211,750,000 All other assets 193,159,000 187,732,000 TOTAL ASSETS $ 419,543,000 $ 399,482,000 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities $ 91,439,000 $ 96,302,000 Loans payable, net of unamortized debt discount 292,087,000 243,184,000 All other liabilities 7,666,000 7,905,000 TOTAL LIABILITIES 391,192,000 347,391,000 TOTAL STOCKHOLDERS’ EQUITY 28,351,000 52,091,000 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 419,543,000 $ 399,482,000 HARROW, INC.

Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; the ongoing communications with the U.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

The Company encourages Harrow stockholders to review these documents, which provide additional details concerning the historical results and future expectations for the business

Based on: Earnings release + Q1 2026 deck + parent 8-K + 10-K — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

SEC original ↗Harrow, Inc. — 10-K Annual report10-KMar 2, 2026

Strategy & priorities

Our co-pay program is a strategic investment intentionally designed to capture patient market share early in the year when insurance resets and out-of-pocket costs are highest.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

By strategically absorbing these initial buy-down costs, we have effectively seeded a much larger, highly profitable, and recurring revenue base that will compound over the coming quarters.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

From a strategic perspective, we entered 2026 with a clear mandate: invest to scale our commercial organization and unlock the full potential of our portfolio .

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

As I write this letter, the expansion of our sales force is complete, and our new representatives are entering the field and beginning to engage physicians, expand access, and build awareness across our markets.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

VEVYE Market Share Gains, Sales Force Expansion, and Coverage Growth During the first quarter following preferred coverage with the largest manager of commercial lives in the U.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Risks & headwinds

” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

htm EX-99.2 Exhibit 99.2 26 th Quarterly Letter to Stockholders May 11, 2026 Dear Harrow Stockholders: The first quarter of 2026 saw unprecedented market demand for VEVYE ® and an unavoidable modeling challenge related to our new commercial coverage.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow’s control, including risks and uncertainties described from time to time in its Securities and Exchange Commission (“SEC”) filings, such as the risks and uncertainties related to the Company’s ability to make commercially available its FDA-approved products and compounded formulations and technologies, and FDA approval of certain drug candidates in a timely manner or at all.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

For a list and description of those risks and uncertainties, please see the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2026, and other filings with the SEC.

SEC original ↗Harrow, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Legal Proceedings 49 Item 4.

SEC original ↗Harrow, Inc. — 10-K Annual report10-KMar 2, 2026

Documents

Earnings deck slides

0 decks with slide view

Harrow, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors